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Abstract
Objective—To investigate the most susceptible genetic loci in systemic sclerosis (SSc) with
genome-wide association study (GWAS).
Methods—A genome-wide association study was performed in 137 patients with systemic
sclerosis and 564 controls from Korea using the Affymetrix Human SNP Array 5.0. After fine
mapping study, the results were replicated in 1,107 SSc patients and 2,747 controls from a US
Caucasian population.
Results—The SNPs (rs3128930, rs7763822, rs7764491, rs3117230 and rs3128965) of HLA-
DPB1 and –DPB2 on chromosome 6 formed a distinctive peak with log p-values (p =8.16 ×
10−13) for association with SSc susceptibility. Subtyping analysis of HLA-DPB1 showed that
DPB1*1301 (p = 7.61×10−8) and DPB1*0901 (p = 2.56×10−5)were the most susceptible subtypes
for SSc in Koreans. In US Caucasians, two pairs of SNPs, rs7763822/rs7764491 and rs3117230/
rs3128965, showed strong association with SSc patients who had either circulating anti-DNA
topoisomerase I (p = 7.58 × 10−17/4.84 × 10−16) or anti-centromere autoantibodies (p = 1.12 ×
10−3/3.2 × 10−5), respectively.
Conclusion—Our GWAS in Koreans revealed that the region of HLA-DPB1 and –DPB2
contains the most susceptible loci to Korean SSc. The confirmatory studies in US Caucasians
indicated that specific SNPs of the HLA-DPB1 and/or –DPB2 were strongly associated with US
Caucasian SSc patients who were positive to anti-topoisomerase I or anti-centromere
autoantibodies.
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Introduction
Systemic sclerosis (SSc) is a rare and complex connective tissue disease of unknown
etiology characterized by fibrosis and vasculopathy of skin and internal organs, as well as
several, mutually exclusive, disease- specific circulating autoantibodies (1,2). SSc can be
clinically sub-classified based on patterns of skin fibrosis into limited and diffuse forms (3).
In addition, the majority of SSc patients (90%) have circulating anti-nuclear autoantibodies
(ANA) (2). The three most common autoantibodies (auto-Abs) are anti-DNA topoisomerase
I (topo I), anti-RNA polymerase III, and anti-centromere antibodies, in which the first two
auto-Abs tend to be associated with diffuse SSc (2,4), the last one being strongly correlated
with limited SSc, although these associations are not complete (2,5).
Genetic predisposition is widely believed to contribute to SSc. However, the low prevalence
of SSc (approximately 0.0007--0.049%) (6,7) and clinical/serological heterogeneity make
genetic studies of SSc difficult with some differing results reported for the same genes in
different ethnic groups. Examples of such discrepancies are the reports of the genes of
connective tissue growth factor (CTGF) (8,9), protein tyrosine phosphatase non-receptor 22
(PTPN22) (10–13) and transforming growth factor (TGF-β) (14–16) in association with SSc.
Although some of these reported genes might have susceptibility markers for SSc in specific
ethnic populations, the candidate gene approach used in the studies might miss other genes
that could be more important to SSc susceptibility. Herein, we used GWAS approach to
conduct a two-step genetic association study in four independent populations to identify the
susceptibility markers for SSc.
Material and Methods
Study Subjects
We examined 4 different ethnic populations (Koreans, Caucasians, African Americans and
Hispanics). Korean study population was composed of 151 SSc patients diagnosed
according to the ACR preliminary criteria for SSc (17). All Korean patients were enrolled
from Seoul National University Hospital between January 1998 and 2007. Genomic DNA
was extracted from whole blood using standard methods. A total of 137 cases which passed
the DNA quality check were entered into the GWAS using Affymetrix Genome-Wide
Human SNP Array 5.0. A total of 133 cases which showed >95% of call rates, were finally
entered into the case-control analysis. The mean age at diagnosis was 42 years ranging from
4 to 74 years. Mean duration of the disease was 10 years and the mean time from diagnosis
to blood sampling was 5 years. Anti-Topo-I antibodies were measured with ELISA and anti-
centromere antibodies were determined by passive immnunodiffusion using HEp-2 cell line.
There were 79 positive vs 48 negative for anti-TopoI (It was not determined in 6 cases) and
16 positive vs 117 negative for anti-centromere antibodies. There were 66 diffuse and 67
limited form of SSc patients, according to SSc classification (3).
The 600 healthy controls were randomly selected from 10,000 healthy Koreans belonging to
Korean Association Resource (KARE) Project, based on the frequency-matching on sex
with the cases. The mean age of the controls was 52.5 years. The same platform (Affymetrix
Genome-Wide Human SNP Array 5.0) was used for the whole-genome scan of the controls.
After excluding cases with low call rate less than 95%, mismatched sex and potential
relatives, a total of 557 controls were finally entered into the case-control analysis. The
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institutional review board of Seoul National University Hospital approved the study and all
patients and controls provided written consents.
There were 1,107 Caucasians, 70 African Americans (AA) and 61 Hispanics who met the
ACR criteria for SSc and corresponding controls (447 Caucasians, 90 of each for AA and
Hispanics) were enrolled in the Division of Rheumatology, University of Texas Health
Science Center at Houston (UTHSC-Houston). In addition, 2,300 Caucasian controls were
selected from NIH data base of Genotype and Phenotype (dbGaP) found at
http://www.ncbi.nlm.nih.gov/gap. Enrolled SSc patients were routinely examined for
circulating anti-topoisomerase I (topo I) and anti-centromere protein autoatibodies using
passive immunodiffusion against calf thymus extracts or indirect immunofluorescence
patterns on HEp-2 cells, respectively. There were 183 positive vs. 917 negative for anti-topo
I, and 316 positive vs. 784 negative for anti-centromere antibodies (7 cases are
undetermined). There were 419 diffuse and 654 limited form of SSc (3). The study was
approved by the institutional review boards of the University of Texas Health Science
Center at Houston. All the individual patients and controls provided written consent.
GWAS analysis
Among the 500,568 SNPs present in Affymetrix Whole Genome Human SNP Array 5.0,
440,734 SNPs were accessible after excluding hidden SNPs. Q-Q plot was obtained in the
condition of p-value > 0.0001 for Hardy-Weinberg equilibrium and call-rate > 0.95 (Figure
1). The most significant SNPs were determined to be rs3128930, re7763822, rs7764491,
rs3117230 and rs3128965 and they went into the fine mapping process.
Fine mapping
For Koreans, we performed a fine mapping focusing on HLA-DPB1 and -DPB2 regions
with 137 SSc cases and 548 healthy controls in whom DNA was available. For HLA-DPB1,
highly variable exon 2 of the gene was DNA-sequenced to determine subtype of HLA-
DPB1. For the other region including HLA-DPB2, total 22 tag SNPs were selected with r2
threshold of 0.8 and minor allele frequency over 5% in HapMap Japanese panel data (release
22) using the Haploview version 4.1 (18,19). In tag SNPs, 17 SNPs which are included in
Affymetrix SNP chip were forced to be included.
For replication studies, TaqMan Assays were used for SNPs rs3128930, re7763822,
rs7764491, rs3117230 and rs3128965 genotyping with an ABI 7900HT Fast Real-Time
PCR System in Caucasian, African American and Hispanic populations. Genotyping results
of all five SNPs passed quality tests for Hardy-Weinberg equilibrium (p > 0.001) and calling
rate (>95%). Two groups of Caucasian controls from the NIH data base and UTHSC-
Houston local controls showed concordant association with Caucasian SSc patients.
Statistical analysis
The association of specific SNPs with the disease or a subset of the disease was analyzed by
the comparison of minor allele frequencies of the cases and controls, with significance
determined by p-values of chi-square tests. The odds ratio of cases’ having a selected SNP
compared with the controls’ and its relevant 95% confidence intervals were also determined.
For GWAS, The threshold for declaring significance after Bonferroni correction for
adjusting multiple tests was p<1.43×10−7. It was p<2.2×10−3 for the fine mapping study
(n=22) and p<0.01 for the replication study (n=5). All the association tests were based on
the comparison of alleles. PLINK (20) and SAS 9.1.3 (SAS Institute Inc., Cary, NC, USA)
were used for the statistical analysis. Linkage disequilibrium analysis for HLA-DPB1 and –
DPB2 regions was performed with Haploview, version 4.1 (19).
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Results
We first examined a Korean population who are relatively homogenous in which 62.2% of
patients are positive for anti-topo I auto-Abs (based on Korean patients enrolled in this
project). We performed a GWAS in 137 Korean SSc patients and 564 sex-matched Korean
controls using the Affymetrix Human SNP Array 5.0 containing 440,734 accessible human
SNPs. The GWAS showed a distinctive peak of SNP log p-value (p = 8.16 × 10−13 for
association with SSc) (Figure 1). The peak was formed with the SNPs rs3128930,
rs7763822, rs7764491, rs3117230 and rs3128965, which were located in the region of HLA-
DPB1 and –DPB2 (a psuedogene) on chromosome 6p (Figure 1, 2). Fine mapping analysis
of this region confirmed that rs3128930, rs7763822 and rs7764491 were the SNPs
accounting for associations with Korean SSc (Figure 2, Table 1). Interestingly, the
association was even stronger in patients who were positive for anti-topo I auto-Abs
(rs3128930, p = 1.70 × 10−22, OR 5.15, 95% CI 3.62–7.34) (Table 1). These SNPs also were
associated with the diffuse form of SSc, but not the limited form of SSc (Supplementary
Table 1). Subtyping of HLA-DPB1 showed that HLA-DPB1*1301 (21.0% in SSc vs. 5.5%
in controls), DPB1*0901 (12.0% vs. 2.6%) and DPB1*030101 (10.0% vs. 4.3%) were
significantly more represented in anti-topo I positive patients than controls (Table 2). SNPs
corresponding to previous SSc associated reported genes, such as PTPN22 (10), AIF1(21),
TNF(22), CTLA-4 (23), and CTGF (8), fell within the significance thresholds of 10−5–10−6
advocated for gene-based scans, as well as the Bonferroni correction for multiple
comparisons (24).
To confirm these results, we used TaqMan Assays to reexamine the 5 SNPs with the
strongest association from the Korean GWAS screen in 1,107 US Caucasian SSc patients
(collected from US), of whom 16% were positive for anti-topo I, and 2,747 normal controls,
of which 447 were from our local collections (Houston, Texas, US.) and 2,300 were from
the NIH data base of Genotype and Phenotype (dbGaP) (http://www.ncbi.nlm.nih.gov/gap).
The SNPs rs7763822 and rs7764491 showed highly significant associations with SSc
patients who were positive for anti-topo I auto-Abs (p = 7.58 × 10−17 and 4.84 × 10−16,
respectively) (Table 3). The HLA-DPB1*1301 allele which occurs in only 3% of US
Caucasians was found in 25% of anti-topo I positive patients and conferred the strongest risk
by exact logistic regression (p=0.0001, OR=14) of any HLA class II allele (unpublished
results). The SNPs rs3128965 and rs3117230 showed strong associations with SSc patients
who were positive for anti-centromere auto-Abs (p = 3.20 × 10−5 and 1.12 × 10−3,
respectively) (Table 3). In addition, the pair of anti-topo I associated SNPs also showed a
weaker association with the diffuse form of SSc (p = 0.0070 and 0.014 for rs7763822 and
rs7764491 respectively) (Supplementary Table 2). The genetic concordance of the patients
with anti-topo I positivity and the diffuse form of SSc supports clinical observations that
these two traits within SSc commonly overlap (2,4). However, the anti-centromere
associated SNP pairs did not show strong associations with the limited form of SSc that
usually occurs in patients with anti-centromere auto-Abs (2,5). The SNP rs3128930 showed
only a marginal p value of 0.041 in the limited form of SSc patients who were positive for
anti-centromere auto-Abs (Supplementary table 2). Further analysis of Caucasian patients
who are negative for anti-topo I or anti-centromere autoantibodies indicated that they have
marginal or no association with the genotypes of all the 5 SNPs (Table 3). In contrast, highly
significant differences were observed in the comparisons of patients with and without anti-
topo I or anti-centromere autoantibodies using corresponding anti-topo I or anti-centromere
associated SNP pairs (rs7763822 and rs7764491 pair, p ≤ 2.86×10−18 or rs3128965 and
rs3117230 pair, 4.77×10−4 respectively) (Supplementary Table 3). Interestingly, marginally
significant differences (0.05 > p ≥ 0.01) were also observed in the comparison of patients
with the limited and the diffuse forms of SSc using both pairs of SNPs but the autoantibody
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associations were the strongest, perhaps because HLA alleles are specific immune response
genes (Table 3, and supplementary Table 2).
Finally, we studied these same SNPs in African Americans and Hispanics with limited
numbers of cases and controls (70 cases vs. 90 controls and 61 cases vs. 90 controls,
respectively). Although, the numbers of subjects examined in these two populations were
small, the SNPs rs7764491 and rs7763822 showed a consistently strong association with
anti-topo I positive SSc in both African Americans (p=9.05×10−3, OR=4.23, 95% CI=1.33–
13.48 for both SNPs) and Hispanics (7.98×10−4, OR=5.51, 95% CI=1.85–16.43 and
p=7.21×10−4, OR=5.57, 95% CI=1.87–16.62, respectively) (Supplementary Table 4,
Supplementary Table 5).
Discussion
In studies of SSc, a human complex disease, there have been inconsistent reports of genetic
associations from different study populations (8–16). The rareness and the heterogeneity of
SSc may contribute at least in part to such discrepancies. In the studies herein, we applied a
two-step approach, in which a GWAS was first conducted in a relatively homogenous
Korean SSc population, and then was followed by a confirmatory study in other populations.
Our findings of SSc-associated HLA-DPB1 and -DPB2 on the basis of autoantibodies,
represent the first replicable report in Asians, Caucasians, African-Americans and Hispanics.
These complementary studies in four independent populations provide strong support for
these identified genetic makers to confer susceptibility to subgroups of SSc patients.
HLA-DPB1, located centromeric to other HLA class II molecules, shows relatively low
linkage disequilibrium with other extended MHC haplotypes (25). Although it was not
studied as extensively as HLA-A, -B, -C or -DR, it has similar antigen-presentation function
to activate CD4+ T cells (26). Its genetic polymorphisms have been found to be associated
with chronic berylliosis (27), graft-vs-host disease (28), juvenile rheumatoid arthrtitis (29),
insulin dependent diabetes mellitus (30) and sarcoidosis (31). Some studies have suggested
the possible roles of HLA-DPB1 in SSc, in the context of HLA-A, B, C and DR molecules
(32–34). Typically, HLA-DPB1 *1301 was previously reported to associate with anti-topo I
in SSc patients in several independent studies, although each of these studies appeared to
have less statistical power with smaller sample size (34–36). The results of Korean GWAS
and US confirmatory studies herein identified that specific SNPs of HLA-DPB1 and –DPB2
are strongly associated with SSc, especially to those patients with auto-antibodies to topo I
or centromere protein, and that the HLA-PDB1 may be the most important susceptibility
gene to Korean SSc.
Our studies indicate that sub-classification and population origin may be two critical factors
in identifying genetic susceptibility markers for SSc. Such is evidenced in our lack of
association in Caucasian SSc with any of the 5 SNPs found in the Korean GWAS until we
took into account those subgroups defined by clinically diffuse and limited forms, but
especially by specific autoantibody status (anti-topo I and anti-centromere positives). In
addition, this notion may also explain previous inconsistent reports of SSc associated genes
in different populations, as well as the fact that these genes were not identified in our GWAS
of Koreans.
Importantly, the genetic differentiations of SSc with distinctive serological and clinical
features in our studies suggest that SSc should not be considered as a single disease. While
SSc, like other human complex diseases, is currently incurable, sub-classification of SSc on
the basis of genetic polymorphisms for disease susceptibility may provide a new dimension
for exploring pathogenesis and treatment of this disease. Our results strongly indicate that
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sub-classification of SSc on the basis of autoantibodies against topo I and centromeric
proteins is important in defining disease susceptibility genes in this heterogeneous disease.
Despite the successful identification of SSc susceptibility genes of HLA-DPB1 and –DPB2
in our studies, it has several limitations. First, the number of SSc patients for GWAS may
not be large enough to distinguish some other true disease risk SNPs from the statistical
noise of false positive SNPs by using stringent statistical threshold in the studies. The power
of GWAS calculated with the assumption of 10% difference of minor allele frequency was
75.0% (37). Second, majority of Korean SSc patients in the studies were positive for anti-
topo-I autoantibodies. Accordingly, genetic predisposition factors for SSc with other SSc
autoantibodies may be better unveiled by a GWAS in other populations. Third, the numbers
of Hispanics and African American may not be enough for adequate power of the study.
Nonetheless, the SNPs of HLA-DPB1 and –DPB2 showed a distinctively strong association
with anti-topo-I positive SSc in our two-step approach of genetic studies. The results
confirmed previous reports of this genetic susceptibility region to SSc, and raised the
importance of sub-classification of SSc in understanding of disease pathogenesis.
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Figure 1.
Identification of the major locus associated with SSc in genome wide scan of Koreans. A
total of 440,734 SNPs were evaluated in 133 patients with SSc and 557 healthy controls. A)
Quantile-quantile plot compares the distributions of observed P-values with expected null P
values. B) Distribution of –Log10 P values are plotted against chromosomes.
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Figure 2.
HLA-DPB as a culprit region for susceptibility to systemic sclerosis. –Log10P values are
depicted around the HLA-DPB region. All genes in the region are also displayed above the
linkage disequilibrium (LD) map. LD between pairs of SNPs is depicted with linkage blocks
in which bright red block represents disequilibrium coefficient (D’) of 1.0 and white block
D’ of 0.0. Orange bar above the LD map represents high LD SNPs which show significant
association (r2>0.8) with culprit SNPs.
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